Assessing left ventricular systolic function in children with a history of Kawasaki disease

Table 1 Clinical features of three groups

	KD with CAD (n = 54)	KD without CAD (n = 46)	Controls (n = 51)	P
Male	41 (76%)	29 (63%)	34 (67%)	0.350
Age (months)	139.44 ± 25.27	144.41 ± 26.98	138.90 ± 24.46	0.510
Heart rate (bmp)	78.83 ± 10.59	75.56 ± 10.63	74.37 ± 14.50	0.150
SBP (mmHg)	108.20 ± 13.77	111.59 ± 12.92	110.63 ± 10.63	0.375
DBP (mmHg)	60.96 ± 11.59	61.09 ± 13.89	64.74 ± 9.76	0.188
BSA (m²)	1.35 ± 0.23	1.41 ± 0.22	1.34 ± 0.22	0.323
Interval from onset to exam (months)	116.83 ± 18.04	118.00 ± 20.93	/	0.765
Interval from onset to IVIG treatment (days)	10.36 ± 4.76	8.53 ± 3.34	/	0.145
Treatment strategy of using cardiovascular drug (1^a/2^b)	5/49	4/42	/	0.922
Dipyridamole^c	23/54	24/46	/	0.339
Complete KD	18 (33%)	21 (46%)	/	0.208

BSA body surface area; CAD coronary artery dilation; DBP diastolic blood pressure; IVIG intravenous immunoglobulin; KD Kawasaki disease; SBP systolic blood pressure
^a: Aspirin is administered at 80 to 100 mg/kg per day in 4 doses with IVIG, continue high dose aspirin until day 14 of illness and 48 to 72 h after fever cessation. When high-dose aspirin is discontinued, clinicians begin low-dose aspirin (3 to 5 mg/kg per day) and maintain it until the patient shows no evidence of coronary changes by 6 to 8 weeks after the onset of illness. After 6 to 8 weeks, aspirin is adjusted to a lower dose (2 to 3 mg/kg per day) until 6 months [4]
^b: Clinicians begin low-dose aspirin (3 to 5 mg/kg per day) and maintain it until the patient shows no evidence of coronary changes by 6 to 8 weeks after the onset of illness. After 6 to 8 weeks, aspirin is adjusted to a lower dose (2 to 3 mg/kg per day) until 6 months [4]
^c: 2 to 6 mg/kg per day in 3 divided doses [4]

ISSN: 1471-2261